Table 1. Characteristics of studies included in the two meta-analyses evaluating cftDNA in EGFR mutation detection.
| First author | Country | Year | Detection methods | Female (%) | Adenocarcinoma (%) | Ever smokers (%) | No. of samples | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|---|---|---|
| Kimura H (37) | Japan | 2006 | ARMS | 37.3 | 85.2 | NA | 11 | 75 | 40 |
| Kimura H (38) | Japan | 2007 | ARMS | 33.3 | 73.8 | 66.7 | 42 | 75 | 97 |
| He C (46) | China | 2009 | ME-PCR | 36.6 | 75.4 | 53 | 18 | 89 | 100 |
| Yung TK (26) | China | 2009 | Digital PCR | NA | NA | NA | 29 | 100 | 94 |
| Kuang Y (47) | USA | 2009 | ARMS | 81.5 | NA | NA | 43 | 70 | 85 |
| Bai H (48) | China | 2009 | DHPLC | 46.5 | 74.3 | 44.8 | 230 | 97 | 92 |
| Sriram KB (49) | Australia | 2011 | ME-PCR | 33.9 | 56.3 | 93.7 | 64 | 50 | 100 |
| Jiang B (50) | China | 2011 | ME sequencing | 31 | 72.4 | 62.1 | 58 | 78 | 100 |
| Taniguchi K (51) | Japan | 2011 | BEAMing | 65.9 | 95.5 | NA | 44 | 73 | 0 |
| Brevet M (52) | USA | 2011 | Sequenom | 51.6 | 96.8 | 54.8 | 31 | 44 | 85 |
| Goto K (33) | Japan | 2012 | AS-APEX | 87.6 | NA | 9 | 86 | 43 | 100 |
| Nakamura T (53) | Japan | 2012 | I-PCR-QPM | 51.3 | 100 | 46.2 | 70 | 45 | 100 |
| Hu C (54) | China | 2012 | HRM | 50 | 58.3 | 45.8 | 24 | 100 | 0 |
| Huang Z (55) | China | 2012 | DHPLC | 46.7 | 78 | 41.4 | 822 | 64 | 85 |
| Xu F (56) | China | 2012 | ARMS | 39.2 | 84.3 | NA | 34 | 50 | 100 |
| Yam I (57) | China | 2012 | AS-APEX | 60 | 94.3 | 14.3 | 35 | 100 | 80 |
| Jing CW (58) | China | 2014 | HRM | 42.5 | 58.3 | NA | 120 | 64 | 97 |
| Liu X (59) | China | 2013 | ARMS | 34.9 | 98.8 | 54.7 | 86 | 68 | 100 |
| Lv C (60) | China | 2013 | DHPLC | 54.5 | NA | 45.5 | 6 | 0 | 100 |
| Zhang H (61) | China | 2013 | MEL | 43 | 75.6 | 51.2 | 86 | 68 | 100 |
| Kim ST (62) | Korea | 2013 | PNA-LNA PCR clamp | 38.6 | 70.2 | 56.1 | 57 | 66 | 93 |
| Zhao X (39) | China | 2013 | ME-PCR | 31.5 | 65.8 | 51.4 | 111 | 35 | 98 |
| Kim HR (63) | Korea | 2013 | PNAClamp | NA | NA | NA | 40 | 17 | 100 |
| Li X (plasma) (64) | China | 2014 | ARMS | 42.5 | 78 | 46.8 | 141 | 48 | 95 |
| Li X (serum) (64) | China | 2014 | ARMS | 44 | 79.6 | 43.5 | 108 | 40 | 96 |
| Weber B (41) | Denmark | 2014 | Cobas EGFR blood test | 49 | 95 | 91 | 196 | 61 | 96 |
| Douillard JY (42) | Europe | 2014 | ARMS | NA | NA | NA | 652 | 66 | 99 |
| Wang S (65) | China | 2014 | ARMS | 48.5 | 80.6 | 46.3 | 74 | 22 | 97 |
ARMS, amplification refractory mutation system; ME-PCR, mutant-enriched-PCR; DHPLC, denaturing high-performance liquid chromatography; ME-sequencing, Mutant-enriched sequencing; BEAMing, beads, emulsion, amplification and magnetics; AS-APEX, allele-specific arrayed primer extension; I-PCR-QPM, inhibiting-PCR-sequencing probe method; HRM, high-resolution melting; MEL, mutant-enriched liquid chip; PNA-LNA, peptide nucleic acid-locked nucleic acid; NA, not available